Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury
Vassilios J. Bezzerides, … , Bruce M. Spiegelman, Anthony Rosenzweig
Vassilios J. Bezzerides, … , Bruce M. Spiegelman, Anthony Rosenzweig
Published June 16, 2016
Citation Information: JCI Insight. 2016;1(9):e85904. https://doi.org/10.1172/jci.insight.85904.
View: Text | PDF
Research Article Cardiology

CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury

  • Text
  • PDF
Abstract

The mechanisms by which exercise mediates its multiple cardiac benefits are only partly understood. Prior comprehensive analyses of the cardiac transcriptional components and microRNAs dynamically regulated by exercise suggest that the CBP/p300-interacting protein CITED4 is a downstream effector in both networks. While CITED4 has documented functional consequences in neonatal cardiomyocytes in vitro, nothing is known about its effects in the adult heart. To investigate the impact of cardiac CITED4 expression in adult animals, we generated transgenic mice with regulated, cardiomyocyte-specific CITED4 expression. Cardiac CITED4 expression in adult mice was sufficient to induce an increase in heart weight and cardiomyocyte size with normal systolic function, similar to the effects of endurance exercise training. After ischemia-reperfusion, CITED4 expression did not change initial infarct size but mediated substantial functional recovery while reducing ventricular dilation and fibrosis. Forced cardiac expression of CITED4 also induced robust activation of the mTORC1 pathway after ischemic injury. Moreover, pharmacological inhibition of mTORC1 abrogated CITED4’s effects in vitro and in vivo. Together, these data establish CITED4 as a regulator of mTOR signaling that is sufficient to induce physiologic hypertrophy at baseline and mitigate adverse ventricular remodeling after ischemic injury.

Authors

Vassilios J. Bezzerides, Colin Platt, Carolin Lerchenmüller, Kaavya Paruchuri, Nul Loren Oh, Chunyang Xiao, Yunshan Cao, Nina Mann, Bruce M. Spiegelman, Anthony Rosenzweig

×

Figure 1

Cardiac expression of CITED4 produces physiological cardiac hypertrophy.

Options: View larger image (or click on image) Download as PowerPoint
Cardiac expression of CITED4 produces physiological cardiac hypertrophy....
(A) Western blot demonstrating CITED4 from whole-heart lysates after 3 weeks of expression by removal of doxycycline (Doxy) in transgenic mice expressing tTA and CITED4-FLAG. (B) Quantification of CITED4 expression as compared with control mice in iCITED4 without doxycycline (3.04- ± 0.63-fold) or with doxycycline (1.13- ± 0.13-fold); n = 4 mice per group, *P < 0.05 by 1-way ANOVA for serial comparisons. (C) Restricted cardiac expression of CITED4-Flag in the double-positive (tTA+/CITED4+) transgenics as demonstrated by Western blot from lysates from multiple tissues. (D) Gross and microscopic histology of representative samples, including H&E (left panels) and MTS for fibrosis (right panels). Scale bars: 50 μm. (E) Increases in heart weight to tibial length for males (8.36 ± 0.35 mg/mm vs. 6.84 ± 0.32 mg/mm) and for females (6.62 ± 0.22 mg/mm vs. 5.72 ± 0.08 mg/mm). n = at least 5 animals per group. (F) Fractional shortening before and after induction of iCITED4 for 3 weeks and 6 weeks, respectively; n = 8–12 males per group. (G) Increase in relative mass index after 3 weeks of induction in CITED4 transgenics remains stable for at least 6 weeks of expression. Relative increase in LV mass for CITED4 transgenics as compared with controls: 27.7% ± 5.2% at 3 weeks and 25.1% ± 7% at 6 weeks. For all graphs: significance determined by the Student’s t test unless otherwise specified; *P < 0.05, **P < 0.01.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts